Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Graph

AKBA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $49.13M; Cost of revenue $10.42M; Research and development $14.06M; Selling, general and administrative $28.17M.
  • 2026-03-31: Revenue $53.54M; Cost of revenue $12.29M; Research and development $14.81M; Selling, general and administrative $30.44M.
  • 2025-12-31: Revenue $57.62M*; Cost of revenue $12.54M*; Research and development $26.65M*; Selling, general and administrative $26.09M*.
  • 2025-09-30: Revenue $58.77M; Cost of revenue $9.38M; Research and development $14.94M; Selling, general and administrative $29.09M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

AKBA revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Auryxia$25.46MLicense CollaborationAnd Other Revenue$2.36MLicense Collaboration AndOther Revenue Royalties$100.00KVafseo$21.30MProduct$46.76MRevenue$49.13MCost of revenue$10.42MOperating expenses$45.03MOperating income-$6.33MOther income, net-$7.00KResearch & development$14.06MSelling, general& administrative$28.17MPre-tax income-$8.84MIncome tax$70.00KNet income-$8.91M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

AKBA revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$49.13MRevenue$49.13MCost of revenue$10.42MOperating expenses$45.03MOperating income-$6.33MOther income, net-$7.00KResearch & development$14.06MSelling, general& administrative$28.17MPre-tax income-$8.84MIncome tax$70.00KNet income-$8.91M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$49.13M$10.42M$14.06M$28.17M$45.03M$70.00K-$8.91M
2026-03-31$53.54M$12.29M$14.81M$30.44M$45.95M$126.00K-$9.05M
2025-12-31$57.62M*$12.54M*$26.65M*$26.09M*$53.64M*$1.01M*-$12.20M*
2025-09-30$58.77M$9.38M$14.94M$29.09M$44.93M$615.00K$540.00K
2025-06-30$62.47M$9.92M$11.01M$26.55M$38.46M$0.00$247.00K
2025-03-31$57.34M$7.63M$9.75M$25.74M$36.20M$0.00$6.11M
2024-09-30$37.43M$14.16M$8.49M$26.52M$35.77M$0.00-$20.04M
2024-06-30$43.65M$17.05M$7.65M$26.92M$35.33M(m)-$8.58M
2024-03-31$32.61M$11.61M$9.73M$25.44M$35.94M(m)-$17.98M
2023-09-30$42.05M$18.01M$13.33M$22.71M$37.07M(m)-$14.49M
2023-06-30$56.38M$17.28M$20.20M$27.04M$48.09M(m)-$11.17M
2023-03-31$40.01M$20.19M$19.69M$25.05M$45.41M(m)-$26.88M
2022-09-30$48.71M$38.28M$28.03M$31.89M$60.84M(m)-$54.10M
2022-06-30$126.36M$18.60M$26.03M$32.24M$73.69M(m)$29.45M
2022-03-31$61.70M$31.34M$43.83M$44.57M$88.85M(m)-$63.51M
2021-09-30$48.76M$15.94M$40.47M$46.36M$87.70M(m)-$59.54M
2021-06-30$52.91M$52.49M$37.21M$41.65M$79.76M(m)-$83.04M
2021-03-31$52.30M$34.61M$40.61M$41.33M$82.63M(m)-$69.58M
2020-12-31(m)$63.23M(m)(m)$78.87M$0.00-$87.00M
2020-09-30$59.99M$30.34M$46.86M$40.17M$87.74M$0.00-$59.96M
2020-06-30$90.14M$174.62M$52.82M$35.48M$89.34M$0.00-$175.75M
2020-03-31$88.48M$27.71M$81.23M$37.98M$119.89M$0.00-$60.75M
2019-12-31(m)$38.15M(m)(m)$126.30M-$1.75M-$94.48M
2019-09-30$91.98M$38.26M$74.51M$34.18M$109.62M-$1.28M-$54.59M
2019-06-30$100.80M$37.67M$85.69M$36.07M$122.66M-$845.00K-$58.17M
2019-03-31$72.67M$31.26M$82.35M$34.29M$117.38M-$2.76M-$72.42M
2018-12-31(m)$7.77M(m)(m)$142.24M-$28.34M-$60.05M
2018-09-30$53.17M(m)$70.63M$10.38M$81.01M$0.00-$26.05M
2018-06-30$48.79M(m)$71.92M$12.54M$84.45M$0.00-$34.07M
2018-03-31$45.93M(m)$61.40M$9.02M$70.43M$0.00-$23.42M
2017-12-31(m)(m)(m)(m)$75.95M(m)$15.52M
2017-09-30$41.28M(m)$58.71M(m)$65.46M$0.00-$23.13M
2017-06-30$28.52M(m)$43.75M(m)$50.66M$0.00-$21.52M
2017-03-31(m)(m)$60.05M(m)$65.84M$0.00-$44.54M
2016-12-31(m)(m)(m)(m)$39.58M(m)-$37.86M
2016-09-30(m)(m)$31.24M(m)$36.18M$0.00-$36.31M
2016-06-30(m)(m)$30.88M(m)$36.19M$0.00-$35.78M
2016-03-31$0.00(m)$20.23M(m)$26.05M$0.00-$25.80M
2015-12-31$0.00*(m)(m)(m)$20.05M(m)-$19.86M
2015-09-30(m)(m)$15.60M(m)$19.68M$0.00-$19.48M
2015-06-30(m)(m)$6.50M(m)$10.89M$0.00-$10.69M
2015-03-31$0.00(m)$6.66M(m)$10.90M$0.00-$10.70M
2014-12-31$0.00*(m)(m)(m)$10.61M(m)-$10.37M
2014-09-30(m)(m)$6.65M(m)$9.58M$0.00-$9.35M
2014-06-30(m)(m)$5.53M(m)$7.84M$0.00-$7.62M
2014-03-31(m)(m)$6.16M(m)$9.91M$0.00-$9.70M
2013-12-31(m)(m)(m)(m)$6.20M(m)-$5.95M
2013-09-30(m)(m)$3.24M(m)$4.03M$0.00-$3.77M
2013-06-30(m)(m)$2.45M(m)$3.12M$0.00-$2.83M
2013-03-31(m)(m)$1.90M(m)$2.58M$0.00-$621.00K

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$102.67M$22.71M$28.87M$58.61M$90.98M$196.00K-$17.96M
2025-06-30$119.81M$17.54M$20.77M$52.30M$74.66M$0.00$6.36M
2024-06-30$76.25M$28.65M$17.38M$52.35M$71.26M(m)-$26.57M
2023-06-30$96.38M$37.47M$39.88M$52.09M$93.50M(m)-$38.05M
2022-06-30$187.99M$50.72M$69.86M$76.81M$162.78M(m)-$34.06M
2021-06-30$105.22M$87.10M$77.83M$82.98M$162.39M(m)-$152.62M
2020-06-30$178.62M$202.33M$134.05M$73.47M$209.24M$0.00-$236.50M
2019-06-30$173.47M$68.93M$168.04M$70.36M$240.03M-$3.60M-$130.59M
2018-06-30$94.72M(m)$133.32M$21.56M$154.88M$0.00-$57.49M
2017-06-30$49.38M(m)$103.80M(m)$116.49M$0.00-$66.06M
2016-06-30$0.00(m)$51.11M(m)$62.23M$0.00-$61.58M
2015-06-30$0.00(m)$13.17M(m)$21.79M$0.00-$21.38M
2014-06-30(m)(m)$11.68M(m)$17.75M$0.00-$17.32M
2013-06-30(m)(m)$4.35M(m)$5.70M$0.00-$3.45M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$178.57M$26.93M$35.71M$81.39M$119.59M$615.00K$6.90M
2024-09-30$113.68M$42.81M$25.87M$78.87M$107.04M$0.00-$46.61M
2023-09-30$138.43M$55.48M$53.21M$74.80M$130.57M(m)-$52.54M
2022-09-30$236.70M$89.00M$97.89M$108.69M$223.62M(m)-$88.16M
2021-09-30$153.97M$103.04M$118.30M$129.34M$250.09M(m)-$212.16M
2020-09-30$238.61M$232.67M$180.91M$113.64M$296.97M$0.00-$296.46M
2019-09-30$265.45M$107.19M$242.56M$104.54M$349.65M-$4.88M-$185.18M
2018-09-30$147.89M(m)$203.96M$31.94M$235.90M$0.00-$83.53M
2017-09-30$90.67M(m)$162.51M(m)$181.95M$0.00-$89.19M
2016-09-30$0.00(m)$82.35M(m)$98.42M$0.00-$97.89M
2015-09-30$0.00(m)$28.77M(m)$41.46M$0.00-$40.86M
2014-09-30$0.00(m)$18.33M(m)$27.33M$0.00-$26.66M
2013-09-30(m)(m)$7.59M(m)$9.73M$0.00-$7.22M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$236.20M$39.46M$62.36M$107.48M$173.24M$1.62M-$5.30M
2024-12-31$160.18M$63.18M$37.65M$106.55M$147.47M$0.00-$69.40M
2023-12-31$194.62M$74.15M$63.08M$100.23M$166.73M$0.00-$51.90M
2022-12-31$292.48M$85.57M$129.99M$138.60M$287.69M$0.00-$94.20M
2021-12-31$211.65M$150.67M$147.85M$174.14M$325.48M$0.00-$282.00M
2020-12-31$294.64M$296.48M$218.49M$154.10M$375.99M$0.00-$384.84M
2019-12-31$335.00M$145.34M$322.97M$149.46M$475.95M-$6.63M-$279.66M
2018-12-31$207.74M$7.77M$291.01M$87.06M$378.13M-$28.34M-$143.59M
2017-12-31$181.23M(m)$230.89M$27.01M$257.90M(m)-$73.67M
2016-12-31$1.53M(m)$115.78M$22.21M$138.00M(m)-$135.75M
2015-12-31$0.00(m)$43.02M(m)$61.51M(m)-$60.72M
2014-12-31$0.00(m)$23.26M(m)$37.94M(m)-$37.03M
2013-12-31(m)(m)$8.90M(m)$15.93M(m)-$13.17M
2012-12-31(m)(m)$5.63M(m)$8.52M(m)-$8.20M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33